Y Biologics (representatives Park Young-woo and Jang Woo-ik) announced on the 1st that they would be participating in the ‘International Bio Convention 2023’ (hereinafter referred to as Bio USA).
Bio USA is the world’s largest comprehensive bio convention event hosted by the American Bio Society. More than 8,000 companies from 65 countries around the world are participating to discuss business and partnership. This year, it will be held in Boston, USA from the 5th to the 8th (local time) with the theme ‘Standing for Science’.
Y Biologics will meet with major global pharma and biotech at BioUSA to present its pipelines, including Korea’s first PD-1 immune anti-cancer drug candidate ‘YBL-006’, and discuss the possibility of technology transfer. In addition, it plans to introduce its core technologies, such as the human antibody library ‘Ymax-ABL’, the immuno-cancer drug development technology ‘Ymax-ENGENE’, and the T-cell double antibody platform ‘ALiCE’.
Y Biologics intends to discuss ways to collaborate with foreign biotechs that have independent ADC technology to strengthen joint antibody-drug conjugate (ADC) research and development partnerships. ADC is an anti-cancer technology that combines antibodies and drugs to precisely target cancer cells in a desired area. In December 2020, BioLogics exported YBL-001 technology, an ADC candidate material developed with LegoChem Bioscience, to Pixis Oncology, a US bio company.
An official from Y-Bio Logics said, “Through Bio USA, we will promote the company’s technology and pipelines to major global pharma and biotechnology companies and strive to strengthen partnerships.”
Meanwhile, Y BioLogics currently aims to be listed on the KOSDAQ stock market as a special technology case within this year. To this end, it filed a preliminary review for listing with the Korea Exchange in March. In January, it received an A grade from the Korea Technology Finance Corporation and eCredible and passed the technical evaluation.
